Current studies into retatrutide peptide highlight significant possibility for managing obesity and non-insulin dependent diabetes. The peptide, a dual stimulator of GLP-1 and glucose-dependent insulinotropic polypeptide, seems to offer greater weight reduction and glucose control compared existing therapies. Additional research efforts are needed